Samsung Electronics Co., Ltd.

Korea Institute of Science and Technology

Jae-Young Koh

Dennis W Choi

Sung-Bo Ko

Laura L Dugan

Eu-Gene Oh

Kyung-Hwa Kim

In-Jae Shin

Moo-Ho Won

In-Kyu Chang

Won-Yeob Kim

Young Soo Kim

Hyunjin Kim

Dong Jin Kim

Tae Song Kim

Kyoseon Hwang

Hye Yun Kim

Kyung-Mi Kim

Eon-Kyeom Kim

Myung-Bok Wie

Sejin Lee

Soo Min Cho

Jee Hoon Roh

Tae-Cheon Kang

The present disclosure relates to a diagnostic kit capable of accurately diagnosing diseases or disorders related with abnormal aggregation or misfolding of proteins, including disorders or diseases caused by aggregation of &#x3b2;-amyloid such as Alzheimer's disease as well as disorders or diseases caused by aggregation of other proteins, based on concentration analysis of the aggregated proteins before and after dissociation.

Diagnostic kit for diagnosis of abnormal protein aggregation- or misfolding-related diseases using dissociation of protein aggregates

Novel dialkylhydroxybenzoic acid derivatives containing metal chelating groups are disclosed. The novel compounds are used as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species and/or excess Zn ions, in particular stroke, Parkinson's disease, Alzheimer's disease. The compounds have not only low toxicity but also similar or superior LPO inhibition activity to references. They also effectively inhibit the cerebral neuronal cell death by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.

Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses

The present invention provides novel dialkylhydroxybenzoic acid derivatives containing metal chelating groups and the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species and/or excess Zn ions, in particular stroke, Parkinson's disease, Alzheimer's disease. The compounds of the invention have not only low toxicity but also similar or superior LPO inhibition activity to references. They also effectively inhibit the cerebral neuronal cell death by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.

The present invention provides novel N-alkyl-N-phenylhydroxylamine derivatives containing metal chelating groups, a process for preparing the same, the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species (ROS) and/or excess Zn ions, in particular stroke, Parkinson's disease and Alzheimer's disease. The compounds of the invention possess similar or superior LPO inhibition activity to the reference compounds of Trolox and Ebselen. While showing lower toxicity, they also effectively inhibit the cerebral neuronal cell death caused by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.

N-alkyl-N-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses

The present invention provides novel seleno compounds containing nitrone moiety, a process for preparing the same, the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species, in particular stroke, Parkinson's disease, Alzheimer's disease. The compounds of the invention have similar or superior lipid peroxidation (LPO) inhibition activity to the reference compounds. While showing lower toxicity and better water solubility, they also effectively inhibit the cerebral neuronal cell death caused by ROS and show neuroprotective effects against ischemic neuronal degeneration.

Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses

Growing community of inventors

Seoul, South Korea

Jae-Young Koh